CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
To assess the effects and mechanisms of a CD200R1 agonist administered during the progressive stage of a multiple sclerosis model, we administered CD200R1 agonist (CD200Fc) or control IgG2a during the chronic phase of disease (days 10–30) in mice with experimental autoimmune encephalomyelitis (EAE), induced using myelin oligodendrocyte glycoprotein peptide 35–55 (MOG35–55) peptide. We found that administration of CD200Fc during the chronic stages of EAE reduced disease severity, demyelination, and axonal damage, through the modulation of several key disease mechanisms. CD200Fc treatment suppressed macrophage and microglial accumulation within the CNS, in part through downregulation of adhesion molecules VLA-4 and LFA-1, which are necessary for macrophage migration. Additionally, expression of activation markers MHC-II and CD80 and production of proinflammatory cytokines IL-6, tumor necrosis factor-α, and nitric oxide by CD11b+cells were decreased in both the spleen and CNS in CD200Fc-treated animals. Antigen-presenting cell function in the spleen and CNS was suppressed in CD200Fc-treated mice, but there were no significant alterations on T cell activation or phenotype. CD200Fc increased apoptosis of CD11b+cells but not astrocytes. In contrast, addition of CD200Fc treatment protected oligodendrocytes from apoptosis in vitro and in vivo. Our results demonstrate that CD200R1 agonists modulate both myeloid- and non-myeloid-related mechanisms of chronic disease in the EAE model and may be effective in the treatment of progressive multiple sclerosis and other neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898 · cited 3×
“Microglia and macrophages are important effectors of demyelination and neurodegeneration, and progressive forms of MS are associated with the presence of activated microglia/ macrophages both within plaques and in normal appearing white matter (Bitsch et al., 2000; Kutzelnigg et al., 2005; Zeis et al., 2008).”
BackgroundDendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862 · cited 1×
“Antigen presentation by perivascular APCs is crucial for both EAE disease initiation and potentially propagation (Greter et al., 2005).”
BackgroundExperimental autoimmune encephalomyelitis repressed by microglial paralysis
Heppner, F. L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., Waisman, A., Rülicke, T., Prinz, M., Priller, J., et al. (2005) · Nature Medicine · doi:10.1038/nm1177 · Cited by 732 · cited 1×
“Animal models of MS have demonstrated that microglia definitively contribute to disease development and progression (Taupin et al., 1997; Heppner et al., 2005).”
BackgroundEpitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694 · cited 1×
“Moreover, epitope spreading is mediated through antigen presentation by CNS APCs, subsequently leading to disease propagation (McMahon et al., 2005).”
BackgroundBettelli, E., Baeten, D., Jäger, A., Sobel, R. A., & Kuchroo, V. K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28334 · Cited by 336 · cited 1×
“The cells were used as APCs in an in vitro assay to stimulate naive 2D2 mouse T cells, which can be readily activated by MOG peptide through effective T-cell receptor signaling (Bettelli et al., 2006).”
MethodButovsky, O. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26836 · Cited by 261 · cited 1×
“The presence of IL-4 attenuated microglial TNF- production and reversed blockade of IGF-1 production induced by IFN- , resulting in enhanced oligodendrogenesis (Butovsky et al., 2006).”
BackgroundLyons, A., McQuillan, K., Deighan, B. F., O’Reilly, J.-A., Downer, E. J., Murphy, A. C., Watson, M., Piazza, A., O’Connell, F., Griffin, R., et al. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.05.060 · Cited by 98 · cited 1×
“Interestingly, IL-4-deficient mice exhibit enhanced CNS microglial activation in response to peripheral LPS injection and have decreased neuronal expression of CD200 (Lyons et al., 2009), suggesting that IL-4 regulates microglial activation through enhancement of CD200 expression.”
Background
Cited by
CNS inflammation and neurodegeneration
Chitnis, T., & Weiner, H. L. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90609 · Cited by 470
Self-citationGonzález, H., Elgueta, D., Montoya, A., & Pacheco, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.07.012 · Cited by 352
Dysregulated neuronal–microglial cross-talk during aging, stress and inflammation
Jurgens, H. A., & Johnson, R. W. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2010.11.014 · Cited by 179
Zhang, S., Wang, X.-J., Tian, L.-P., Pan, J., Lu, G.-Q., Zhang, Y.-J., Ding, J.-Q., & Chen, S.-D. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-154 · Cited by 154
“Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, Reif K, Chitnis T: CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis.”
BackgroundInfluentialModification of Biomaterials with a Self‐Protein Inhibits the Macrophage Response
Kim, Y. K., Que, R., Wang, S., & Liu, W. F. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300532 · Cited by 56
Metadata
- Authors
- Liu, Y., Bando, Y., Vargas-Lowy, D., Elyaman, W., Khoury, S. J., Huang, T., Reif, K., & Chitnis, T.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-02-10
- Volume
- 30
- Issue
- 6
- Pages
- 2025-2038
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W1993967286
- Cited by
- 86
- References
- 8
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis. https://app.cochat.ai/papers/10.1523/jneurosci.4272-09.2010
- The paper
- Liu, Y., Bando, Y., Vargas-Lowy, D., Elyaman, W., Khoury, S. J., Huang, T., Reif, K., & Chitnis, T. (2010). CD200R1 Agonist Attenuates Mechanisms of Chronic Disease in a Murine Model of Multiple Sclerosis. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.4272-09.2010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.